Patent
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
| العنوان: | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
|---|---|
| Patent Number: | 8,673,924 |
| تاريخ النشر: | March 18, 2014 |
| Appl. No: | 11/788847 |
| Application Filed: | April 20, 2007 |
| مستخلص: | In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An example pyrazolo[1,5-a]pyrimidine compound useful in the present invention is shown below: [chemical expression included] |
| Inventors: | Guzi, Timothy J. (Chatham, NJ, US); Paruch, Kamil (Garwood, NJ, US); Dwyer, Michael P. (Scotch Plains, NJ, US); Doll, Ronald J. (Convent Station, NJ, US); Girijavallabhan, Viyyoor M. (Parsippany, NJ, US); Mallams, Alan (Hackettstown, NJ, US); Alvarez, Carmen S. (Livingston, NJ, US); Keertikar, Kartik M. (East Windsor, NJ, US); Rivera, Jocelyn (Monmouth Junction, NJ, US); Chan, Tin-Yau (Edison, NJ, US); Madison, Vincent S. (Mountain Lakes, NJ, US); Fischmann, Thierry O. (Scotch Plains, NJ, US); Dillard, Lawrence W. (Skillman, NJ, US); Tran, Vinh D. (Fountain Valley, CA, US); He, Zhenmin (Shanghai, CN); James, Ray Anthony (Bensalem, PA, US); Park, Haengsoon (Plainsboro, NJ, US); Paradkar, Vidyadhar M. (Somerville, NJ, US); Hobbs, Douglas Walsh (Yardley, PA, US); Kirschmeier, Paul (Basking Ridge, NJ, US); Bannerji, Rajat (Morristown, NJ, US) |
| Assignees: | Merck Sharp & Dohme Corp. (Rahway, NJ, US), Pharmacopeia, LLC (San Diego, CA, US) |
| Claim: | 1. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 2. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient an amount of a first compound, which is a compound selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof; and an amount of at least one second compound, said second compound being an anti-cancer agent; wherein the amounts of the first compound and said second compound result in a therapeutic effect. |
| Claim: | 3. The method of claim 2 , further comprising radiation therapy. |
| Claim: | 4. The method of claim 2 , wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, pegylated liposomal doxorubicin, liposomal doxorubicin, doxorubicin liposomal, docetaxel, paclitaxel, etoposide, irinotecan, topotecan, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, ara-C, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, bevacizumab, trastuzumab, tositumomab, bortezomib, ibritumomab, arsenic trioxide, Vinorelbine, Porfimer, cetuximab, Liposomal, Thiotepa, Altretamine, Melphalan, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, satriplatin, Gemtuzumab ozogamicin, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzumab. |
| Claim: | 5. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient: a composition comprising: (i) a therapeutically effective amount of at least one compound selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof, and (ii) temozolomide. |
| Claim: | 6. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof by inhibiting CDK1 or CDK2, comprising administering to said patient a therapeutically effective amount of the compound: [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 7. The method of claim 6 further comprising administering radiation therapy. |
| Claim: | 8. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the compound: [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 9. The method of claim 8 further comprising administering radiation therapy. |
| Claim: | 10. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient a composition comprising (i) the compound: [chemical expression included] or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, pegylated liposomal doxorubicin, liposomal doxorubicin, doxorubicin liposomal, docetaxel, paclitaxel, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, ara-C, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, bevacizumab, trastuzumab, tositumomab, bortezomib, ibritumomab, arsenic trioxide, Vinorelbine, Porfimer, cetuximab, Liposomal, Thiotepa, Altretamine, Melphalan, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, satriplatin, Gemtuzumab ozogamicin, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzumab. |
| Claim: | 11. The method of claim 10 , further comprising the administration of radiation therapy. |
| Claim: | 12. A method of treating chronic lymphocytic leukemia, breast cancer, non-small cell lung cancer, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof comprising administering to said patient a composition comprising (i) the compound: [chemical expression included] or a pharmaceutically acceptable salt thereof, and (ii) temozolomide. |
| Claim: | 13. The method of claim 12 , further comprising the administration of radiation therapy. |
| Claim: | 14. A method of treating chronic lymphocytic leukemia, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 15. The method of claim 14 wherein said cancer being treated is chronic lymphocytic leukemia. |
| Claim: | 16. The method of claim 14 wherein said cancer being treated is acute myleogenous leukemia. |
| Claim: | 17. The method of claim 14 wherein said cancer being treated is acute lymphoblastic leukemia. |
| Claim: | 18. The method of claim 14 wherein said cancer being treated is mantle cell leukemia. |
| Claim: | 19. The method of claim 14 wherein said method further comprises administering at least one anti-cancer agent. |
| Claim: | 20. The method of claim 19 wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, pegylated liposomal doxorubicin, liposomal doxorubicin, doxorubicin liposomal, docetaxel, paclitaxel, etoposide, irinotecan, topotecan, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, ara-C, cytoxan, cyclophosphamide, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, bevacizumab, trastuzumnab, tositumomab, bortezomib, ibritumomab, arsenic trioxide, Vinorelbine, Porfimer, cetuximab, Liposomal, Thiotepa, Altretamine, Melphalan, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, satriplatin, Gemtuzumab ozogamicin, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzumab. |
| Claim: | 21. A method of treating chronic lymphocytic leukemia, acute myleogenous leukemia, acute lymphoblastic leukemia, or mantle cell lymphoma in a patient in need thereof comprising administering to said patient a composition comprising (i) the compound: [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 22. The method of claim 21 wherein said cancer is chronic lymphocytic leukemia. |
| Claim: | 23. The method of claim 21 wherein said cancer is acute myleogenous leukemia. |
| Claim: | 24. The method of claim 21 wherein said cancer is acute lymphoblastic leukemia. |
| Claim: | 25. The method of claim 21 wherein said cancer is mantle cell leukemia. |
| Current U.S. Class: | 5142/593 |
| Patent References Cited: | 3907799 September 1975 O'Brien et al. 5571813 November 1996 Rühter et al. 5602136 February 1997 Rühter et al. 5602137 February 1997 Rühter et al. 6107305 August 2000 Misra et al. 6180627 January 2001 Blagg et al. 6383790 May 2002 Shokat 6413974 July 2002 Dumont et al. 10223917 December 2003 0628559 April 2002 WO 91/18904 December 1991 WO 92/18504 October 1992 WO 95/35298 December 1995 WO 99/10325 March 1999 WO 00/26210 May 2000 WO 02/10162 February 2002 WO 02/22610 March 2002 WO 02/32893 April 2002 WO 02/40485 May 2002 WO 02/50079 June 2002 WO 02/64211 August 2002 WO 03/091256 November 2003 WO 03/101993 December 2003 WO 2007/044449 April 2007 |
| Other References: | Fischer, P.M.; Gianella-Borrador A.;CDK inhibitors in clinical development for the treatmentof cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970. cited by examiner Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, I Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477. I. cited by examiner Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977. cited by examiner Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596. cited by examiner Vippagunta et. al., “Crystalline Solids,” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001). cited by examiner Gavezzotti, “Are Crystal Structures Predicatable?” Acc. Chem. Res., vol. 27, pp. 309-314 (1994). cited by examiner Anderson et al, “Preparation of Water-Soluble Compounds Through Salt Formation”, The Practice of Medicinal Chemistry, pp. 739-754 (1996). cited by applicant Berge et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19 (1977). cited by applicant Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”, Cancer Research, vol. 57, pp. 3375-3380 (Aug. 15, 1997). cited by applicant Feng et al, “Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position”, J. Med. Chem., vol. 40, pp. 3726-3733 (1997). cited by applicant Gennaro (ed.), “Remington's Pharmaceutical Sciences”, 18th Edition, Mack Publishing Co., Easton, Pennsylvania (1990). cited by applicant Gould, “Salt Selection for Basic Drugs”, International J. of Pharmaceutics, vol. 33, pp. 201-217 (1986). cited by applicant Greene et al, Protective Groups in Organic Synthesis, Wiley, New York (1981). cited by applicant Gudmundsson et al, Synthesis of Novel Imidazo[1,2-α]pyridines with Potent Activity Against Herpesviruses, Organic Letters, vol. 5, No. 8, pp. 1369-1372 (2003). cited by applicant Gupton et al, An Alternative Preparation of the 2-Dimethylaminomethylene-1,3-bis (dimethylimmonio)propane Salt from Phosphonoacetic Acids and Some Applications in Heterocyclic Synthesis, J. Heterocyclic Chem., vol. 28, pp. 1281-1285 (1991). cited by applicant Heinisch et al, “Synthesen und Reaktionen von Pyridazinderivaten, 3. Mitt.”, Monatschefte fur Chemie, vol. 104, pp. 1372-1382 (1973). cited by applicant Higuchi et al, “Pro-Drugs as Novel Delivery Systems”, vol. 14, A.C.S. Symposium Series (1987). cited by applicant Hosoi et al, “Evidence for cdk5 as a Major Activity Phosphorylating Tau Protein in Porcine Brain Extract”, J. Biochem., vol. 117, pp. 741-749 (1995). cited by applicant Kim et al, “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”, Journal of Medical Chemistry, vol. 45, pp. 3905-3927 (2002). cited by applicant López-Rodriguez et al, Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors, J. Med. Chem., vol. 44, pp. 4505-4508 (2001). cited by applicant Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines”, Chem. Pharm. Bull., vol. 10, pp. 620-626 (1962). cited by applicant Meijer et al, “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”, Eur. J. Biochem, vol. 243, pp. 527-536 (1997). cited by applicant Novinson et al, “Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-triazines1” Journal of Medicinal Chemistry, vol. 19, No. 4, pp. 517-520 (1976). cited by applicant Novinson et al, “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-α]pyrimidines”, J. Med. Chem., vol. 20, No. 2, pp. 296-299 (1977). cited by applicant Ongkeko et al, “Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage”, J. Cell Sci., vol. 108, p. 2897 (1995). cited by applicant Ragan et al, “Shock Sensitivity of a Vinamidinium Bis-Perchlorate Reagent and Demonstration of a Lower Energy Alternative”, Synlett, vol. 8, pp. 1172-1174 (2000). cited by applicant Roche, “Bioreversible Carriers in Drug Design”, American Pharmaceutical Association and Pergamon Press (1987). cited by applicant Senderowicz et al, “Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns”, Journal of Clinical Oncology, vol. 16, No. 9, pp. 2986-2999 (Sep. 1998). cited by applicant Shiota et al, “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-α]pyrimidine Derivatives”, Chem. Pharm. Bull., vol. 47, No. 7, pp. 928-938 (1999). cited by applicant Shiota et al, “Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-α]pyrimidine”, Journal of Organic Chemistry, vol. 64, pp. 453-457 (1999). cited by applicant Vesely et al, “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem, vol. 224, pp. 771-786 (1994). cited by applicant The Orange Book (Food & Drug Administration, Washington, DC (http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, May 6, 2010. cited by applicant International Search Report for related case PCT/US2008/004907, mailed Jul. 1, 2008. cited by applicant Brief Report: Randomized Phase 2 Study of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Erlotinib in Patients with Non-Small Cell Lung Cancer, 18 pages. cited by applicant |
| Primary Examiner: | Moore, Susanna |
| Attorney, Agent or Firm: | Parr, Richard S. Ginkel, Laura M. |
| رقم الانضمام: | edspgr.08673924 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |